Exposed Bone in Mouth: Causes, Symptoms, and Treatments

Exposed bone in the mouth is exactly what it sounds like: jawbone or palatal bone that has lost its protective covering of gum tissue and sits bare inside the oral cavity. When that bone fails to heal on its own within about eight weeks, the condition is classified as osteonecrosis of the jaw, a slow-progressing problem that most often strikes the lower jaw because of its relatively poor blood supply.¹ The causes range from certain medications and radiation therapy to infections, anatomic quirks, and chronic substance use, and the right treatment depends almost entirely on which cause is driving the problem.

Medications That Starve the Jawbone

The most widely recognized trigger for exposed jawbone is a group of drugs called bisphosphonates, prescribed for osteoporosis and for cancer patients whose disease has spread to bone. Denosumab, another bone-strengthening medication, carries the same risk. The condition these drugs can cause is known as medication-related osteonecrosis of the jaw (MRONJ). Bisphosphonates work by slowing down the cells that break down and recycle old bone. That is useful for keeping bones dense, but it also means the jawbone loses its ability to remodel and repair itself after routine injuries like tooth extractions or even the everyday stress of chewing.²

Risk factors stack on top of the medication itself. Dental infections, tooth extractions, older age, and certain anatomic features of the jaw all raise the probability of MRONJ developing. The risk is substantially higher with intravenous bisphosphonates (the type cancer patients typically receive) than with the oral tablets used for osteoporosis, though both carry some degree of risk. Animal research has shown that bisphosphonate-treated subjects develop more dead bone fragments, called sequestra, after tooth extractions compared to untreated controls, reinforcing the link between these drugs and impaired bone healing.³ Beyond bisphosphonates and denosumab, antiangiogenic drugs used in cancer treatment have also been implicated.⁴

Radiation Therapy and the Jawbone

People treated with radiation for head and neck cancers face a distinct but related problem called osteoradionecrosis. Radiation damages the tiny blood vessels that feed the jawbone, leaving the bone hypoxic and fragile. A large observational study of 572 patients treated with radiation found that about 6% developed exposed bone in the mouth within two years. Most of those cases appeared within the first six months after treatment, and the mandible accounted for roughly three-quarters of all episodes.⁵

Confirmed osteoradionecrosis was diagnosed in about 3% of that same group. The risk went up with higher radiation doses to the jaw area, with tooth extractions performed before radiation, and with tobacco use. The most commonly affected patients were those whose primary cancer was in the oropharynx or oral cavity, which makes sense since those tumors sit close to the jawbone and the radiation fields tend to overlap it.⁵ About one in five cases of exposed bone in the study persisted for more than six months, underscoring that while some episodes self-resolve, a meaningful fraction become chronic.

Infections That Destroy Oral Bone

Bone exposure does not always require medications or radiation. Severe gum disease can progress to the point where bone becomes visible. Necrotizing ulcerative gingivitis, an aggressive bacterial infection of the gums that is more common in people with weakened immune systems, can advance through the soft tissue until it reaches bone. In one staging study, about 7% of patients with necrotizing gingival disease had advanced to the point of mucosal necrosis or bone exposure.⁶

Osteomyelitis, an infection of the bone itself, is another route. It can develop after a dental extraction, after a jaw fracture, or as a complication of untreated tooth infections. One documented case following a routine dental procedure showed a characteristic “moth-eaten” appearance of the jawbone on imaging, with dead bone fragments forming in and around the extraction socket.⁷ In osteomyelitis, bacteria colonize the bone, trigger inflammation, and cut off local blood supply, producing patches of dead bone that eventually shed through the overlying gum tissue.

Anatomic Factors and Bony Growths

Some people have bony prominences inside their mouths called tori, harmless overgrowths of bone on the palate or along the inside of the lower jaw. These lumps are covered by a thin layer of mucosa with little cushioning tissue underneath. In some cases, chronic irritation from chewing, poorly fitting dentures, or even hard or sharp foods can wear through that thin covering, leaving the bone underneath exposed.

Researchers have suggested that repeated chewing forces produce microtrauma and reduce blood flow through the thin tissue overlying these bony prominences, eventually compromising its integrity. Cases of spontaneous bone exposure over mandibular tori have been documented, where no obvious injury triggered the breakdown.⁸ The good news is that torus-related bone exposure is generally manageable with surgical removal of the bony growth and is not linked to the progressive bone destruction seen in osteonecrosis.

Cocaine and Palatal Bone Destruction

Chronic cocaine use, particularly the nasal insufflation (snorting) route, can destroy bone in the roof of the mouth. The drug constricts blood vessels and has a direct caustic effect on the tissues it contacts. Over time, repeated exposure leads to inflammation, tissue death, and the progressive loss of septal cartilage and palatal bone, eventually creating a perforation between the mouth and the nasal cavity.⁹

A systematic review of cocaine-related palatal perforations found that most lesions affected the hard palate, with a smaller proportion involving the soft palate or both. The perforations averaged about 19 millimeters across, and the most common complaints were nasal-sounding speech and food or liquid regurgitating through the nose.¹⁰ In severe cases, destruction spreads beyond the palate to the paranasal sinuses and nasal support structures, causing visible facial deformity.⁹ Unlike medication-related osteonecrosis, the damage here will continue to worsen as long as drug use continues, so cessation is the single most important intervention.

What Exposed Bone Feels Like

Exposed bone does not always announce itself with dramatic pain. In early stages, you might notice a rough, hard patch along your gum line or the roof of your mouth that was not there before. Running your tongue over it feels distinctly different from normal tissue. Some people discover it only because their dentist spots it during a routine exam.

As the condition progresses, the symptoms typically intensify:

Pain: dull aching in the jaw that can become sharp, especially when eating or if the area is touched.
Swelling: the gum tissue around the exposed area often becomes puffy, red, or tender.
Bad taste or odor: dead bone and the bacteria that colonize it produce a persistent foul taste or noticeable bad breath.
Numbness or tingling: if the inferior alveolar nerve runs through the affected zone, the lip or chin on that side can feel numb.
Loose teeth: as the supporting bone deteriorates, nearby teeth lose their anchor.
Difficulty eating: jaw pain, loose teeth, and the risk of food getting trapped against raw bone all make mealtimes challenging.

The impact on daily life is measurable. Studies comparing quality-of-life scores in patients with osteonecrosis of the jaw to population norms have found significant worsening across several dimensions, including eating discomfort, interrupted meals, self-consciousness, irritability, and overall life satisfaction.¹¹ Cancer and osteoporosis patients who develop MRONJ experience a further drop in quality of life beyond what their underlying disease already causes, with social function and the ability to fulfill daily roles particularly affected.¹²

How It Is Diagnosed

Diagnosis starts with a clinical exam. A dentist or oral surgeon looking at exposed, yellowish-white bone in the mouth with no healing after eight weeks has a strong clinical diagnosis. But imaging is needed to understand how far the damage extends beneath the surface. Standard panoramic dental X-rays can miss mild cases or underestimate the extent of bone involvement. Cone-beam computed tomography (CBCT), a 3D imaging technique, consistently outperforms panoramic imaging in detecting and characterizing these lesions.¹³

CBCT can reveal the full extent of bone destruction, identify loose bone fragments, and show whether the damage has reached neighboring structures like the sinus floor or the nerve canal. For mild early-stage disease, the advantage is most pronounced: panoramic images often look nearly normal, while CBCT reveals clear bony changes.¹⁴ This matters for early detection, because the sooner bone changes are caught, the more treatment options remain on the table.

Conservative and Non-Surgical Treatments

For early-stage disease where the exposed bone is small and symptoms are mild, conservative management is the first line. This typically means antibiotics to control infection, antimicrobial mouth rinses like chlorhexidine, careful monitoring, and removing any obvious source of ongoing trauma (adjusting dentures, for instance). A systematic review comparing conservative and surgical approaches found that conservative treatment tends to yield better outcomes in patients with early-stage MRONJ.¹⁵

One combination that has attracted attention is pentoxifylline and vitamin E (sometimes abbreviated PENT-E). Pentoxifylline is a drug that improves blood flow in small vessels, and vitamin E acts as an antioxidant. A phase II trial in patients with refractory osteoradionecrosis of the jaw found that 89% of 18 patients achieved complete recovery after six months or more of daily treatment with this combination.¹⁶ A separate observational study used the same combination in cancer patients with medication-related osteonecrosis and reported symptom relief in all seven patients, with radiographic evidence of new bone filling in prior defects.¹⁷ These are small studies, and the approach has not been tested in large randomized trials, but the results are encouraging for patients who have run out of easier options.

Hyperbaric oxygen therapy, which delivers pure oxygen under pressure to boost tissue healing, is sometimes offered to patients with osteoradionecrosis. Its actual benefit is harder to pin down. A meta-analysis found no significant difference between hyperbaric oxygen plus standard care and standard care alone for treating osteoradionecrosis.¹⁸ Combined data from two randomized clinical trials showed a trend favoring hyperbaric oxygen (70% healing versus 51%), but the trials were underpowered and the difference did not reach statistical significance.¹⁹ A multidisciplinary panel at one major cancer center concluded that routine use of hyperbaric oxygen for prevention or management of osteoradionecrosis is not supported by consistent evidence.²⁰ In short, hyperbaric oxygen might help some patients, but the evidence is too thin to recommend it as a standard treatment.

When Surgery Becomes Necessary

Advanced-stage osteonecrosis, or cases that fail conservative management, usually require surgery. The same systematic review that favored conservative care for early disease found that surgical treatment produced better outcomes in patients with advanced MRONJ, particularly when the necrotic bone was removed and regenerative materials were applied to the surgical site.¹⁵

Surgical approaches range in scope depending on how much bone is involved:

Sequestrectomy: removal of loose, dead bone fragments. This is the least invasive surgical option and is suitable when the necrotic bone has already separated from the healthy bone around it.
Marginal resection: removing a strip of diseased bone from the edge of the jaw while preserving the jaw’s overall continuity. A large study of 206 patients who underwent surgery for MRONJ reported that marginal mandibulectomy was by far the most common procedure, performed in about three-quarters of cases.²¹
Segmental resection: removing a full-thickness section of the jaw. This is reserved for extensive disease and requires reconstruction to restore jaw function.

After sequestrectomy, soft tissue coverage is important to prevent re-exposure of bone. One approach uses the buccal fat pad, a natural pad of fat in the cheek, to fill the surgical defect. A study of ten patients treated with sequestrectomy followed by buccal fat pad reconstruction reported complete healing in all cases, with no residual pain, inflammation, or postoperative infection.²²

For the most severe cases, where a segment of the jaw must be removed entirely, surgeons can reconstruct the defect using vascularized free flaps, grafts of bone taken with their own blood supply from elsewhere in the body (the fibula is the most common donor site, used in about 80% of cases). A systematic review of this technique reported a 96% flap success rate and osteonecrosis recurrence in only about 6% of patients.²³ Mandibulectomy with free flap reconstruction has been recommended specifically for the most advanced stages and for cases that have failed other treatments.²⁴

Emerging Approaches

Research is exploring several newer strategies. Among the most promising is teriparatide, a form of parathyroid hormone that stimulates new bone formation rather than just slowing bone loss. Early clinical results in MRONJ patients have been described as encouraging.⁴ The logic is straightforward: if the problem is bone that cannot remodel, a drug that actively builds new bone might break the cycle. Platelet-rich fibrin, a concentrate derived from the patient’s own blood, is being studied as a surgical adjunct. Animal research combining surgical resection with platelet-rich fibrin and low-level laser therapy showed improved wound healing and bone regeneration compared to surgery alone.²⁵ These approaches are still experimental, and there is no consensus on when or how to use them in routine practice.

Prevention Before and During High-Risk Treatments

The strongest message in the clinical literature is that preventing exposed bone is far easier than treating it. For patients about to start intravenous bisphosphonates, guidelines recommend a thorough dental examination beforehand. Any dental work that requires bone healing, including extractions, implant placement, and surgical gum procedures, should be completed before the medication begins.²⁶ Good oral hygiene and regular dental visits are essential throughout treatment.

The same principle holds for radiation therapy: teeth with a poor prognosis should be extracted well in advance of starting treatment to avoid post-radiation extractions, which carry a much higher risk of osteoradionecrosis. During bisphosphonate or denosumab therapy, avoiding bone trauma and treating dental infections promptly are the two most important protective measures.²⁷ Pre-therapy dental care does not eliminate risk entirely, but it reduces it meaningfully. Non-surgical dental procedures can often be used to maintain oral health during treatment, further lowering the chance of exposed bone developing.²⁸

Exposed Bone After a Tooth Extraction

Not every case of visible bone after a dental procedure signals osteonecrosis. In the first days after a tooth extraction, it is not unusual for a small amount of bony socket wall to be visible or palpable, especially if the blood clot that normally fills the socket is lost (a common complication called dry socket). Dry socket is painful and annoying, but it typically heals with conservative care and is a fundamentally different problem from osteonecrosis.

The key distinction is time. A dry socket usually resolves within one to two weeks with appropriate wound care. If bone remains exposed for more than eight weeks and shows no sign of healing, that crosses the clinical threshold for osteonecrosis. For patients on bisphosphonates or who have had head and neck radiation, any extraction socket that is not healing on schedule warrants a prompt visit to an oral surgeon. Early recognition means earlier intervention, and the evidence consistently shows that early-stage disease responds better to conservative treatment than advanced disease.

If you are taking bone-strengthening medication and your dentist recommends an extraction, do not panic, but do make sure everyone on your care team is communicating. Your oncologist or prescribing physician and your dentist should coordinate on whether a drug holiday is appropriate, what precautions to take during the procedure, and what follow-up monitoring looks like. That coordination is where prevention happens.